We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Cord Blood Transplants May Outperform Matched Sibling Donors

By LabMedica International staff writers
Posted on 16 Jun 2020
When a cancer patient needs a bone marrow transplant, there are four common donor sources: A matched related donor (sibling), a matched unrelated donor (from a donor database), a half-matched donor, or umbilical cord blood.

There are advantages and disadvantages to each approach, but consensus has generally ranked a matched sibling first, followed by a matched unrelated donor, with cord blood and half-matched donors reserved for patients without either of the first two options.

Image: A unit of cord blood that can be used for stem cell transplants (Photo courtesy of Catholic University of Valencia).
Image: A unit of cord blood that can be used for stem cell transplants (Photo courtesy of Catholic University of Valencia).

Hematologists at the University of Colorado Anschutz Medical Campus (Aurora, CO, USA) compared outcomes among adult matched related donor (MRD) patients undergoing peripheral blood stem cell transplantation and adult patients undergoing double unit cord blood transplantation (CBT), between 2010 and 2017. A total of 190 CBT patients were compared with 123 MRD patients. Median follow-up was 896 days (range, 169-3,350) among surviving CBT patients and 1,262 days (range, 249-3,327) among surviving MRD patients. For MRD donors, median infused cells were 6.07 × 106 CD34/kg (range, 2.99-9.66).

The scientists reported that in the comparison of 190 patients receiving cord-blood transplants with 123 patients receiving transplants from the "gold standard" of matched sibling donors showed no difference in survival outcomes between these two approaches, with significantly fewer complications due to chronic graft-versus-host disease in patients receiving transplants from cord blood. In addition to showing a decrease in the chance of graft-versus-host disease, which develops when a transplanted blood system attacks a patient's tissues, the study shows a slightly lower rate of relapse in these patients undergoing transplant with cord blood.

Jonathan A. Gutman, MD, CU Cancer Center investigator and director of the allogeneic stem cell transplantation program and senior author of the study, said, “It turns out that for adults, it's very hard to find a single cord blood unit that meets the parameters we know need to be met in terms of size. To overcome this barrier, we often use two units from different sources. We think there are important advantages of cord blood, especially with respect to graft-versus-host disease. Previously, we've taken a position recommending cord blood over matched unrelated donors, and now we show that cord blood may even out-compete the gold standard of matched sibling donors.” The study was published on May 22, 2020 in the journal Blood Advances.

Related Links:
University of Colorado Anschutz Medical Campus


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Latest Hematology News

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Handheld White Blood Cell Tracker to Enable Rapid Testing For Infections